Icatibant

Icatibant, the active ingredient in the product Icatibant, is a bradykinin B2 receptor antagonist presented as a 30 mg (0.3 mL) subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH USA supplies Icatibant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled product handling and regulatory compliance. The company provides robust cold‑chain logistics and comprehensive documentation to meet global market requirements.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.

- Hereditary angioedema (HAE) acute attacks: Provides rapid relief of swelling episodes in adult patients.

Common side effects are generally mild and related to the injection site or transient systemic reactions.

Common Side Effects: - Injection site pain: discomfort at the site of administration. - Redness or erythema: localized skin reddening. - Swelling at injection site: mild edema around the injection. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Severe angioedema: unexpected swelling beyond intended effect. - Hypotension: notable drop in blood pressure. - Urticaria: hives or widespread skin rash. - Severe injection‑site reaction: necrosis or infection. - Infection: localized or systemic infection at the injection site.

Precautions should be observed to minimize risk and ensure safe use. - Pregnancy: safety not established; use only if benefit outweighs potential risk. - Breastfeeding: unknown safety; consider caution. - Renal impairment: monitor as drug clearance may be reduced. - Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; monitor for angioedema. - Known hypersensitivity: avoid use in patients with documented allergy to icatibant or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that affect bradykinin pathways or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may raise angioedema risk. - Angiotensin receptor blockers (ARBs): similar potential to increase bradykinin‑mediated reactions. - Other bradykinin B2 antagonists: may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid balance and blood pressure. - Corticosteroids: could mask signs of infection. - Antihistamines: may modify response to allergic symptoms.